Beijing Scitop Bio-tech Co., Ltd. researches, develops, produces and sells probiotic lactic acid bacteria, postbiotics, edible probiotic products, animal and plant microecological preparations and compound food additives primarily in China. The company, founded in 2003 and headquartered in Beijing's Huairou Science City, offers specific strains such as Lacticaseibacillus casei Zhang, isolated from traditional fermented sour mare's milk in Inner Mongolia, which regulates human intestinal flora and prevents upper respiratory tract infections; Bifidobacterium animalis subsp. lactis Probio-M8, derived from breast milk of healthy women, which relieves asthma, acute respiratory infections in infants and regulates immunity; Bifidobacterium animalis subsp. lactis ProSci-246, applied in ready-to-eat probiotic products for weight reduction in obese individuals; and Probio-M9, alongside biotechnology services, consulting and technology transfers. Its products serve the food industry, health medical sector, animal husbandry, agricultural planting and sports nutrition, including as a global strategy partner of China's State General Administration of Sports Training Administration; it targets human, animal and soil health solutions with applications in finished food and beverage products, dietary supplements and biotic ingredients. Beijing Scitop Bio-tech listed on the Shenzhen Stock Exchange's ChiNext Growth Enterprise Market board under ticker 300858.SZ in July 2020, enabling expanded R&D and production capacity; in August 2024, a subsidiary received a 20 million yuan government grant; and in 2025, it commercialized Bifidobacterium animalis subsp. lactis ProSci-246 in market-ready products following scientific validation of its obesity-related benefits, while participating in industry events such as Vitafoods Asia 2025 and Vitafoods Europe 2025.